Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ionis Pharmaceuticals Inc's Business Segments
Ionis Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Ionis Operations
Total Revenue
$ 268
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Ionis Operations100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Ionis Operations | $ 268 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Research and Development Revenue55.7%
- Collaborative Agreement Revenue49.7%
- Commercial44.3%
- Royalty28.3%
- SPINRAZA Royalties20%
- Salanersen16.8%
- Product11.6%
- DAWNZERA Sales9.9%
- Sapablursen7.5%
- Wainus Royalties6.1%
- WAINUA Joint Development Revenue6%
- Other Commercial4.3%
- Other Royalties2.3%
- Tryngolza1.7%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Research and Development Revenue | $ 149 | 55.7% |
| Collaborative Agreement Revenue | $ 133 | 49.7% |
| Commercial | $ 119 | 44.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
11 more categories available
Sign in to unlock the full Ionis Pharmaceuticals Inc dataset.
Description of Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc is a biopharmaceutical company that has its headquarters in Carlsbad, California, United States. The company's main focus is on the development of RNA-targeted therapeutics which can help in treating various diseases. The company has been in operation since 1989 and it was formerly known as Isis Pharmaceuticals. It changed its name to Ionis Pharmaceuticals in December 201
Ionis Pharmaceuticals has a unique therapeutic approach that involves the development of antisense drug candidates, which are designed to target RNA molecules in the body. The company has a wide range of research and development programs that are focused on developing drugs for different diseases. Some of these diseases include neurological disorders, cardiovascular diseases, and various types of cancer.
One of the company's most well-known products is Spinraza, which is a drug that treats spinal muscular atrophy (SMA). SMA is a genetic disorder that causes progressive muscle weakness and it is one of the leading causes of infant mortality. Spinraza was approved by the US Food and Drug Administration (FDA) in December 2016, and it is now widely used in the treatment of SMA.
In addition to Spinraza, Ionis Pharmaceuticals has several other drugs in clinical development. These drugs include drugs for the treatment of Huntington's disease, cardiovascular disease, and cancer. The company has also been able to establish several collaborations with other pharmaceutical companies, which has helped to leverage its antisense technology to create more effective drugs.
Ionis Pharmaceuticals has a strong financial position and has been able to raise significant amounts of capital over the years. The company's revenue is mainly generated from royalties, licensing fees, and milestone payments from its partnerships. In 2020, the company generated $192 million in revenue, a significant increase from the previous year.
In conclusion, Ionis Pharmaceuticals Inc is a biopharmaceutical company that has gained recognition for its unique approach to RNA-targeted therapeutics. The company's innovative products have shown promising results in the treatment of various diseases, and with its strong financial position, it is well positioned to continue developing cutting-edge therapies in the future.
Ionis Pharmaceuticals has a unique therapeutic approach that involves the development of antisense drug candidates, which are designed to target RNA molecules in the body. The company has a wide range of research and development programs that are focused on developing drugs for different diseases. Some of these diseases include neurological disorders, cardiovascular diseases, and various types of cancer.
One of the company's most well-known products is Spinraza, which is a drug that treats spinal muscular atrophy (SMA). SMA is a genetic disorder that causes progressive muscle weakness and it is one of the leading causes of infant mortality. Spinraza was approved by the US Food and Drug Administration (FDA) in December 2016, and it is now widely used in the treatment of SMA.
In addition to Spinraza, Ionis Pharmaceuticals has several other drugs in clinical development. These drugs include drugs for the treatment of Huntington's disease, cardiovascular disease, and cancer. The company has also been able to establish several collaborations with other pharmaceutical companies, which has helped to leverage its antisense technology to create more effective drugs.
Ionis Pharmaceuticals has a strong financial position and has been able to raise significant amounts of capital over the years. The company's revenue is mainly generated from royalties, licensing fees, and milestone payments from its partnerships. In 2020, the company generated $192 million in revenue, a significant increase from the previous year.
In conclusion, Ionis Pharmaceuticals Inc is a biopharmaceutical company that has gained recognition for its unique approach to RNA-targeted therapeutics. The company's innovative products have shown promising results in the treatment of various diseases, and with its strong financial position, it is well positioned to continue developing cutting-edge therapies in the future.
Segments
Ionis Pharmaceuticals Inc. operates primarily in three key segments that position the company as a leader in the field of RNA-targeted therapies:
1. Antisense Technology: This segment focuses on the development and commercialization of antisense drugs, which are designed to specifically bind to RNA. By targeting the RNA molecules responsible for producing certain proteins involved in various disease processes, these drugs can effectively reduce or eliminate the production of those proteins. Antisense technology represents a groundbreaking approach to treating a range of diseases, particularly genetic disorders, neurological diseases, and some types of cancer. The versatility of this technology allows Ionis to customize its drug candidates to target diseases that have historically been difficult to treat.
2. Generation0+ Technology: Ionis Pharmaceuticals has advanced its antisense platform through the Generation0+ technology, which encompasses next-generation antisense drugs with enhanced therapeutic characteristics. These drugs exhibit improved tissue penetration, increased potency, and longer-lasting effectiveness in the body, which significantly enhances their therapeutic potential across a variety of indications. This segment reflects the companys commitment to innovation and improvement in RNA-targeted therapies, contributing to more effective treatment options for patients.
3. Partnered Programs: Ionis Pharmaceuticals has successfully entered into strategic partnerships with several prominent biopharmaceutical companies, including AstraZeneca, Biogen, and Roche. Through these collaborations, the company is working on the development and commercialization of a variety of drugs aimed at treating different medical conditions. Partnered programs not only expand Ioniss reach but also leverage the expertise and resources of its partners, facilitating greater advancement in drug development timelines and market access.
Products
Ionis Pharmaceuticals boasts a comprehensive and diverse portfolio of products that are at various stages of development. Some of the highlights include:
1. Tegsedi (inotersen): Tegsedi is an FDA-approved drug specifically indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR), which is a rare genetic disorder characterized by the buildup of amyloid proteins. Utilizing Ioniss Generation0+ technology, Tegsedi effectively reduces the production of transthyretin (TTR), mitigating the progression of the disease and improving patients quality of life.
2. Waylivra (volanesorsen): Waylivra is indicated for the treatment of familial chylomicronemia syndrome (FCS), a rare condition that leads to extremely high levels of triglycerides in the bloodstream. By targeting the production of apolipoprotein C-III (apoC-III), a protein implicated in lipid metabolism, Waylivra helps to lower triglyceride levels and prevent devastating complications associated with this disorder.
3. Ionis-FB-LRx: In partnership with Roche, Ionis is developing Ionis-FB-LRx as a potential treatment for various complement-mediated diseases, including age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH). This drug candidate targets the complement system, which plays a critical role in the immune response and inflammation, offering a promising therapeutic avenue for these challenging diseases.
4. Pipeline Programs: Beyond its marketed products, Ionis Pharmaceuticals has a robust pipeline that includes additional antisense drugs in various stages of clinical trials for conditions such as neurodegenerative diseases, cardiovascular disorders, and rare genetic diseases. This pipeline reflects the companys ongoing commitment to advancing RNA-targeted therapies.
Services
Ionis Pharmaceuticals extends its expertise in RNA-targeted therapies by providing a range of services designed to support drug discovery and development efforts, including:
1. Ionis Research Services: This service offering encompasses a full range of customized drug discovery solutions utilizing Ioniss proprietary antisense technology. The research services include target identification, high-throughput screening, lead optimization, and preclinical development. By providing these services, Ionis enables partnering organizations to leverage its scientific expertise in developing their own RNA-targeted therapeutics.
2. Development and Manufacturing Services: With a strong focus on the development and manufacturing of antisense drugs, Ionis Pharmaceuticals offers these critical services to its partners. This includes expertise in formulation development, scale-up manufacturing, and the establishment of quality control processes to ensure that the final drug products meet regulatory standards.
3. Consultancy Services: Ionis also provides consultancy services for biopharmaceutical companies interested in integrating antisense technology into their drug development programs. These services cover a wide array of topics, including the design and optimization of RNA-targeted therapeutics, guidance on preclinical and clinical development strategies, support with regulatory affairs, and insight into best practices for advancing RNA-targeted drug candidates through the development pipeline.
Through these segments, products, and services, Ionis Pharmaceuticals Inc. continues to position itself as a pioneer in biopharmaceutical innovation, particularly in the realm of RNA-targeted therapies, with a focus on improving patient outcomes through cutting-edge science and strategic partnerships.
Ionis Pharmaceuticals Inc. operates primarily in three key segments that position the company as a leader in the field of RNA-targeted therapies:
1. Antisense Technology: This segment focuses on the development and commercialization of antisense drugs, which are designed to specifically bind to RNA. By targeting the RNA molecules responsible for producing certain proteins involved in various disease processes, these drugs can effectively reduce or eliminate the production of those proteins. Antisense technology represents a groundbreaking approach to treating a range of diseases, particularly genetic disorders, neurological diseases, and some types of cancer. The versatility of this technology allows Ionis to customize its drug candidates to target diseases that have historically been difficult to treat.
2. Generation0+ Technology: Ionis Pharmaceuticals has advanced its antisense platform through the Generation0+ technology, which encompasses next-generation antisense drugs with enhanced therapeutic characteristics. These drugs exhibit improved tissue penetration, increased potency, and longer-lasting effectiveness in the body, which significantly enhances their therapeutic potential across a variety of indications. This segment reflects the companys commitment to innovation and improvement in RNA-targeted therapies, contributing to more effective treatment options for patients.
3. Partnered Programs: Ionis Pharmaceuticals has successfully entered into strategic partnerships with several prominent biopharmaceutical companies, including AstraZeneca, Biogen, and Roche. Through these collaborations, the company is working on the development and commercialization of a variety of drugs aimed at treating different medical conditions. Partnered programs not only expand Ioniss reach but also leverage the expertise and resources of its partners, facilitating greater advancement in drug development timelines and market access.
Products
Ionis Pharmaceuticals boasts a comprehensive and diverse portfolio of products that are at various stages of development. Some of the highlights include:
1. Tegsedi (inotersen): Tegsedi is an FDA-approved drug specifically indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR), which is a rare genetic disorder characterized by the buildup of amyloid proteins. Utilizing Ioniss Generation0+ technology, Tegsedi effectively reduces the production of transthyretin (TTR), mitigating the progression of the disease and improving patients quality of life.
2. Waylivra (volanesorsen): Waylivra is indicated for the treatment of familial chylomicronemia syndrome (FCS), a rare condition that leads to extremely high levels of triglycerides in the bloodstream. By targeting the production of apolipoprotein C-III (apoC-III), a protein implicated in lipid metabolism, Waylivra helps to lower triglyceride levels and prevent devastating complications associated with this disorder.
3. Ionis-FB-LRx: In partnership with Roche, Ionis is developing Ionis-FB-LRx as a potential treatment for various complement-mediated diseases, including age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH). This drug candidate targets the complement system, which plays a critical role in the immune response and inflammation, offering a promising therapeutic avenue for these challenging diseases.
4. Pipeline Programs: Beyond its marketed products, Ionis Pharmaceuticals has a robust pipeline that includes additional antisense drugs in various stages of clinical trials for conditions such as neurodegenerative diseases, cardiovascular disorders, and rare genetic diseases. This pipeline reflects the companys ongoing commitment to advancing RNA-targeted therapies.
Services
Ionis Pharmaceuticals extends its expertise in RNA-targeted therapies by providing a range of services designed to support drug discovery and development efforts, including:
1. Ionis Research Services: This service offering encompasses a full range of customized drug discovery solutions utilizing Ioniss proprietary antisense technology. The research services include target identification, high-throughput screening, lead optimization, and preclinical development. By providing these services, Ionis enables partnering organizations to leverage its scientific expertise in developing their own RNA-targeted therapeutics.
2. Development and Manufacturing Services: With a strong focus on the development and manufacturing of antisense drugs, Ionis Pharmaceuticals offers these critical services to its partners. This includes expertise in formulation development, scale-up manufacturing, and the establishment of quality control processes to ensure that the final drug products meet regulatory standards.
3. Consultancy Services: Ionis also provides consultancy services for biopharmaceutical companies interested in integrating antisense technology into their drug development programs. These services cover a wide array of topics, including the design and optimization of RNA-targeted therapeutics, guidance on preclinical and clinical development strategies, support with regulatory affairs, and insight into best practices for advancing RNA-targeted drug candidates through the development pipeline.
Through these segments, products, and services, Ionis Pharmaceuticals Inc. continues to position itself as a pioneer in biopharmaceutical innovation, particularly in the realm of RNA-targeted therapies, with a focus on improving patient outcomes through cutting-edge science and strategic partnerships.